Evidence map›Paper›PMID 34883342›Full record

ArticleCellular immunology2022

Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production.

Marcela T Taruselli, Elizabeth Motunrayo Kolawole, Amina Abdul Qayum, Tamara T Haque, Heather L Caslin, Daniel Abebayehu, Sydney A Kee, Jordan M Dailey, Kaitlyn G Jackson, Jason R Burchett and 6 more

Open access · greenAbstract read
In one paragraph

Article in Cellular immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Tumor-infiltrating mast cells stimulate ICOSJournal of advanced research · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Marcela T TaruselliDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, United States.
Elizabeth Motunrayo KolawoleDepartment of Biology, Virginia Commonwealth University, Richmond, VA 23284, United States.
Amina Abdul QayumDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, United States.
Tamara T HaqueDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, United States.
Heather L CaslinDepartment of Biology, Virginia Commonwealth University, Richmond, VA 23284, United States.
Daniel AbebayehuDepartment of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23298, United States.
Sydney A KeeDepartment of Biology, Virginia Commonwealth University, Richmond, VA 23284, United States.
Jordan M DaileyDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, United States.
Kaitlyn G JacksonDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, United States.
Jason R BurchettDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, United States.
Andrew J SpenceDepartment of Biology, Virginia Commonwealth University, Richmond, VA 23284, United States.
Neha PondicherryDepartment of Biology, Virginia Commonwealth University, Richmond, VA 23284, United States.
Brian O BarnsteinDepartment of Biology, Virginia Commonwealth University, Richmond, VA 23284, United States.
Gregorio GomezUniversity of Houston College of Medicine, Department of Biomedical Sciences, Houston, TX 77204, United States.
David B StrausDepartment of Biology, Virginia Commonwealth University, Richmond, VA 23284, United States.
John J RyanDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, United States. Electronic address: jjryan@vcu.edu.
Virginia Commonwealth University · USUniversity of Houston · US

Funding

GGT Targeting Suppresses Mast Cell Activation by IgE and IL-33R01AI138495 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI RYAN, JOHN J · 2018 to 2022
$2.2M
IGNITE KUH NRSA Training CoreTL1DK132771 · NIDDK · UNIVERSITY OF VIRGINIA · PI PORTILLA, DIDIER · 2021 to 2025
$1.9M
P2X3 is a Female-Dominant Amplifier of Mast Cell FunctionR01AI164710 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI RYAN, JOHN J · 2021 to 2025
$1.8M
Integrated Virginia Research Training Centers in KUH (IGNITE KUH)U2CDK129500 · NIDDK · UNIVERSITY OF VIRGINIA · PI SHARMA, RAHUL · 2021 to 2025
$1.4M
SSRIs Inhibit IgE-mediated Mast Cell FunctionR21AI138494 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI RYAN, JOHN J · 2019 to 2020
$403k
NIAID NIH HHS R01 AI138495NIAID NIH HHS R01 AI164710NIAID NIH HHS R21 AI138494NIDDK NIH HHS TL1 DK132771NIDDK NIH HHS U2C DK129500
6 · The paper itself

Abstract

Statins are HMG-CoA reductase inhibitors prescribed for lowering cholesterol. They can also inhibit inflammatory responses by suppressing isoprenylation of small G proteins. Consistent with this, we previously found that fluvastatin suppresses IgE-mediated mast cell function. However, some studies have found that statins induced pro-inflammatory cytokines in macrophages and NK cells. In contrast to IgE signaling, we show that fluvastatin augments IL-33-induced TNF and IL-6 production by mast cells. This effect required the key mast cell growth factor, stem cell factor (SCF). Treatment of IL-33-activated mast cells with mevalonic acid or isoprenoids reduced fluvastatin effects, suggesting fluvastatin acts at least partly by reducing isoprenoid production. Fluvastatin also enhanced IL-33-induced NF-κB transcriptional activity and promoted neutrophilic peritonitis in vivo, a response requiring mast cell activation. Other statins tested did not enhance IL-33 responsiveness. Therefore, this work supports observations of unexpected pro-inflammatory effects of some statins and suggests mechanisms by which this may occur. Because statins are candidates for repurposing in inflammatory disorders, our work emphasizes the importance of understanding the pleiotropic and possible unexpected effects of these drugs.

Indexed as

AnimalsCells, CulturedFluvastatinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsImmunoglobulin EInflammationInterleukin-33Interleukin-6Killer Cells, NaturalMacrophagesMast CellsMevalonic AcidMiceMice, Inbred BALB CMice, Inbred C57BLFluvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsIl33 protein, mouseImmunoglobulin EInterleukin-33Interleukin-6interleukin-6, mouseMevalonic AcidStem Cell FactorTerpenesTnf protein, mouseTranscription Factor RelATumor Necrosis Factor-alphaAllergyIL-33InflammationMast cellStatin

Identifiers

PMID34883342
PMCPMC8782378
OpenAlexW3216072127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.